Found 48 clinical trials
Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
). Half of the participants will receive immediate cellular therapy followed by sham therapy 6 months later, while the other half will receive immediate sham therapy followed by cellular therapy 6 months
- 0 views
- 24 Jan, 2021
- 1 location
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant
The haematological neoplasia relapse is the cause of higher mortality after allogeneic stem cell transplantation (HSCT). When transplantation fails the most common therapeutic strategy is to increase the antitumor activity of the donor's immune system through the infusion of donor Lymphocytes (DLI). The use of DLI may limit the relapse, …
- 0 views
- 22 Jan, 2021
- 1 location
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
This Research study is being done to characterize the safety, tolerability, and preliminary antitumor activity of the NEXI-002 T cell product (a new experimental therapy), which contains populations of CD8+ T cells targeting multiple Myeloma associated antigen peptides in patients with relapsed refractory multiple myeloma (MM). The study will enroll …
- 0 views
- 27 Jan, 2021
- 4 locations
Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells
The goal of this study is to determine the safety and efficacy of fresh metabolically active allogeneic umbilical cord-derived mesenchymal stromal cells (UC-MSCs) for the treatment of new-onset type 1 diabetes (T1D) and to understand the mechanisms of protection. If proven effective, such a strategy can be used as a …
- 0 views
- 18 Mar, 2021
- 1 location
Patient Reported Outcomes and Patient Education in Cellular Therapy Patients
The purpose of this research is to provide an educational visit addressing common emotional stressors involved in the transplant/CAR-T process, and determine if this added education improves levels of anxiety, depression, and fatigue after transplant/CART in comparison to people who do not receive the brief educational visit.
- 0 views
- 01 May, 2021
- 1 location
Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas
It is believed that the body's immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of tumors. In most patients with advanced cancer, T-cells are not stimulated enough to …
- 13 views
- 18 Jul, 2021
- 2 locations
Adoptive Cellular Therapy and Radiation Therapy After Surgery in Treating Patients With Esophageal Cancer
Cytokine-induced killer (CIK) cells show cytolytic activity against tumor. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining Radiation therapy with adoptive cellular
- 5 views
- 23 Jan, 2021
- 1 location
PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS
This study is to determine the safety and best dose of PRGN-3006 T Cells
- 9 views
- 31 May, 2021
- 1 location
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL
Single center Phase 1 dose escalation trial of the combination of standard-of-care blinatumomab plus Haplo-Mismatched Cellular Therapy (HMCT). HMCT refers to the infusion of donor peripheral
- 0 views
- 14 Feb, 2021
- 1 location
Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial
Spina bifida, or myelomeningocele (MMC), is a disorder where the lower part of the spinal cord of the fetus is exposed, meaning there is no bone or skin covering it. This is dangerous because the spinal cord contains cells which control one's ability to move their legs and walk, and …
- 0 views
- 22 Jul, 2021
- 1 location